Literature DB >> 6823162

Vancomycin.

J E Geraci, P E Hermans.   

Abstract

Vancomycin is a narrow-spectrum bactericidal antistaphylococcal antibiotic that was introduced in 1956 because of its efficacy against resistant penicillinase-producing staphylococci. It was effective for serious staphylococcal infections for which no satisfactory alternative to penicillin G was available at the time. When methicillin and the other semisynthetic penicillins and the cephalosporins were introduced, the role of vancomycin was relegated to the alternative therapy of choice when the penicillins and the cephalosporins could not be used. In the future, vancomycin may be used more frequently in (1) methicillin-resistant Staphylococcus aureus infections, (2) streptococcal endocarditis in conjunction with an aminoglycoside in patients intolerant to penicillin or ampicillin, (3) infections associated with prosthetic devices caused by organisms with multiple antibiotic resistance, and (4) antibiotic-induced enterocolitis associated with Clostridium difficile.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6823162

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

Review 1.  Future prospects and therapeutic potential of streptogramins.

Authors:  E Rubinstein; N Keller
Journal:  Drugs       Date:  1996       Impact factor: 9.546

2.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers.

Authors:  D P Healy; R E Polk; M L Garson; D T Rock; T J Comstock
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

3.  Determination of vancomycin in human serum by high-pressure liquid chromatography.

Authors:  F Jehl; C Gallion; R C Thierry; H Monteil
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

4.  Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Authors:  H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

5.  Exfoliative reaction to vancomycin.

Authors:  D Neal; R Morton; G R Bailie; S Waldek
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-09

6.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

8.  Concentrations of vancomycin in bone and serum of normal rabbits and those with osteomyelitis.

Authors:  K J Wilson; J T Mader
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

9.  Sustained release of antibiotics from injectable and thermally responsive polypeptide depots.

Authors:  Samuel B Adams; Mohammed F Shamji; Dana L Nettles; Priscilla Hwang; Lori A Setton
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2009-07       Impact factor: 3.368

10.  Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique.

Authors:  K Vance-Bryan; D R Guay; S S Gilliland; K A Rodvold; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.